HDCRT Plus Pembrolizumab in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

January 13, 2020

Study Completion Date

February 10, 2020

Conditions
Solid Tumor
Interventions
RADIATION

High-Dose Conformal Radiation Therapy

"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"

DRUG

Pembrolizumab

200 mg

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
lead

James Larner, MD

OTHER

NCT02987166 - HDCRT Plus Pembrolizumab in Advanced Malignancies | Biotech Hunter | Biotech Hunter